Ardea Biosciences Inc., of San Diego, earned a $15 million milestone payment from its partner Bayer HealthCare AG under a 2009 license agreement concerning MEK inhibitor compounds

BHV Pharmaceuticals, of Research Triangle Park, N.C., has entered into a license agreement with Kissei Pharmaceutical Co...Cell Medica Ltd., of London, entered an exclusive license agreement and research collaboration with the Center for Cell and Gene Therapy, Baylor College of Medicine, for the commercialization of a cell-based treatment for cancers associated with the oncogenic Epstein Barr virus

An April 2009 collaboration and license agreement provides Merck Sharp and Dohme Corp. (formerly known as Merck & Co. Inc.) with exclusive global rights to vernakalant oral formulation for the maintenance of normal heart rhythm in patients with atrial fibrillation and provides another Merck affiliate, Merck Sharp & Dohme (Switzerland) GmbH, with exclusive rights outside of the U.S., Canada and Mexico to vernakalant IV formulation for rapid conversion of recent onset atrial fibrillation to sinus

PDL contended that royalties were due under an October 2001 patent license agreement with Celltech Therapeutics Ltd., which was later acquired by UCB

Zealand Pharma AS, of Copenhagen, Denmark, received a €500,000 (US$662,055) milestone payment from Helsinn Healthcare SA, of Lugano, Switzerland, as part of the firms' November 2008 license agreement to develop ZP1846, potent and selective glucagon-like-peptide-2 analogue, as a treatment for chemotherapy-induced diarrhea

Zealand Pharma AS, of Copenhagen, Denmark, received a €500,000 (US$662,055) milestone payment from Helsinn Healthcare SA, of Lugano, Switzerland, as part of the firms' November 2008 license agreement to develop ZP1846, potent and selective glucagon-like-peptide-2 analog, as a treatment for chemotherapy-induced diarrhea

In January 2010, the companies announced a research collaboration and license agreement worth up to $1.4 billion for the research, development and commercialization of DsiRNA pharmaceuticals and drug delivery systems for therapeutic targets in oncology

Cellectis SA, of Paris, and Harvard Apparatus, a division of Harvard Bioscience Inc., of Holliston, Mass., have signed a license agreement that grants Harvard Apparatus the worldwide exclusive right to manufacture and sell, for research use, the full line of electroporation-based instruments, which Cellectis gained in its acquisition of CytoPulse Sciences Inc

Cellectis SA, of Paris, and Harvard Apparatus, a division of Harvard Bioscience Inc., of Holliston, Mass., have signed a license agreement that grants Harvard Apparatus the worldwide exclusive right to manufacture and sell, for research use, the full line of electroporation-based instruments, which Cellectis gained in its acquisition of CytoPulse Sciences Inc

Upon completion of the feasability study, the companies will execute a license agreement

Upon completion of the feasability study, the companies will execute a license agreement

Nautilus Neurosciences Inc., of Bedminster, N.J., and Tribute Pharmaceuticals, of Milton, Ontario, announced an exclusive license agreement for the commercialization of Cambia (diclofenac potassium for oral solution) in Canada

MorphoSys AG, of Martinsried, Germany, said its research and diagnostic antibodies unit AbD Serotec signed a license agreement with the Institute of Cancer Research of London providing the company with worldwide exclusive rights to commercialize a Bromodeoxyuridine antibody clone for research applications

MorphoSys AG, of Martinsried, Germany, said its research and diagnostic antibodies unit AbD Serotec signed a license agreement with the Institute of Cancer Research of London providing the company with worldwide exclusive rights to commercialize a Bromodeoxyuridine antibody clone for research applications

Viamet Pharmaceuticals Inc., of Research Triangle Park, N.C., and Dow AgroSciences LLC, of Indianapolis, a subsidiary of the Dow Chemical Co., entered a crop protection research, option and license agreement to test the use of Viamet's Metallophile technology to develop agricultural compounds with new modes of action

Paion AG, of Aachen, Germany, expanded its desmoteplase license agreement with partner H. Lundbeck A/S, of Copenhagen, Denmark, under which Lundbeck is granted research rights and potential desmoteplase follow-on compounds identified by Paion

Paion AG, of Aachen, Germany, expanded its desmoteplase license agreement with partner H. Lundbeck A/S, of Copenhagen, Denmark, under which Lundbeck is granted research rights and potential desmoteplase follow-on compounds identified by Paion

Ltd., of Taipei, Taiwan, amended its license agreement with Warner Chilcott plc, of Ardee, Ireland, for the development and commercialization of nemonoxacin, a new generation quinolone antibiotic

Ltd., of Tokyo, said they are expanding their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology...Vivalis, of Nantes, France, said the Kitasato Institute signed a research license agreement to evaluate the replication of an undisclosed virus in Vivalis' EB66 cell line for the manufacturing of human vaccines